Exagen (NASDAQ:XGN) Stock Rating Upgraded by KeyCorp

Exagen (NASDAQ:XGN) was upgraded by analysts at KeyCorp from a “sector weight” rating to an “overweight” rating in a research note issued to investors on Wednesday, MarketBeat Ratings reports. The brokerage presently has a $12.00 price target on the stock. KeyCorp’s target price would indicate a potential upside of 42.86% from the stock’s current price. KeyCorp also issued estimates for Exagen’s FY2026 earnings at ($0.31) EPS.

A number of other equities analysts have also issued reports on the company. Canaccord Genuity Group increased their price objective on Exagen from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Tuesday, May 13th. BTIG Research reissued a “buy” rating on shares of Exagen in a report on Wednesday, May 7th. Cantor Fitzgerald cut their target price on Exagen from $8.00 to $7.00 and set an “overweight” rating for the company in a research report on Thursday, May 15th. UBS Group restated an “overweight” rating on shares of Exagen in a research report on Thursday, May 15th. Finally, Craig Hallum began coverage on Exagen in a research report on Wednesday, July 23rd. They issued a “buy” rating and a $12.00 target price for the company. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $11.25.

Exagen Stock Performance

Shares of XGN stock opened at $8.40 on Wednesday. Exagen has a 12-month low of $1.78 and a 12-month high of $9.10. The firm has a market capitalization of $184.80 million, a price-to-earnings ratio of -9.44 and a beta of 1.58. The business has a 50 day simple moving average of $7.15 and a 200 day simple moving average of $5.39. The company has a debt-to-equity ratio of 1.06, a current ratio of 4.95 and a quick ratio of 2.32.

Exagen (NASDAQ:XGN) last issued its quarterly earnings data on Tuesday, July 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.18). Exagen had a negative return on equity of 130.38% and a negative net margin of 28.85%. The business had revenue of $17.20 million during the quarter, compared to analyst estimates of $16.25 million. On average, equities research analysts anticipate that Exagen will post -0.88 EPS for the current year.

Institutional Investors Weigh In On Exagen

Institutional investors have recently added to or reduced their stakes in the company. Northern Trust Corp lifted its position in shares of Exagen by 16.7% during the 4th quarter. Northern Trust Corp now owns 18,375 shares of the company’s stock valued at $75,000 after acquiring an additional 2,630 shares during the last quarter. Huntleigh Advisors Inc. lifted its position in shares of Exagen by 5.7% during the 2nd quarter. Huntleigh Advisors Inc. now owns 87,861 shares of the company’s stock valued at $613,000 after acquiring an additional 4,753 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Exagen during the 1st quarter valued at $25,000. Geode Capital Management LLC lifted its position in shares of Exagen by 11.9% during the 4th quarter. Geode Capital Management LLC now owns 98,057 shares of the company’s stock valued at $402,000 after acquiring an additional 10,442 shares during the last quarter. Finally, Corient Private Wealth LLC acquired a new stake in shares of Exagen during the 4th quarter valued at $45,000. 75.25% of the stock is currently owned by institutional investors and hedge funds.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).